(Dimethylamino)Butyric Acid Diester of Astaxanthin

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (Dimethylamino)Butyric Acid Diester of Astaxanthin
• 英文别名: [4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[4-[4-(dimethylamino)butanoyloxy]-2,6,6-trimethyl-3-oxocyclohexen-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethyl-2-oxocyclohex-3-en-1-yl] 4-(dimethylamino)butanoate
• 化学式: C₅₂H₇₄N₂O₆
• 分子量: 823.169
• InChiKey: BONSOKUHSWVKPP-DXZHKSBLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  12.1
• 重原子数：
  60
• 可旋转键数：
  22
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  93.2
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  3,3'-dihydroxy-β,β-carotene-4,4'-dione 、 4-(二甲胺基)丁酸 盐酸盐 在 4-二甲氨基吡啶 、 1-羟基苯并三唑 、 N,N-二异丙基乙胺 、 N,N'-二异丙基碳二亚胺 作用下， 以 DMF (N,N-dimethyl-formamide) 、 二氯甲烷 为溶剂， 反应 36.0h， 以77.7%的产率得到(Dimethylamino)Butyric Acid Diester of Astaxanthin
  参考文献：
  名称：

  [EN] STRUCTURAL CAROTENOID ANALOGS FOR THE INHIBITION AND AMELIORATION OF DISEASE
  [FR] ANALOGUES DE CAROTENOIDES STRUCTURAUX POUR L'INHIBITION ET LA REDUCTION DE MALADIE

  摘要：

  公开号：

  WO2004011423A3

文献信息

• Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors
  申请人：Lockwood Samuel F.

  公开号：US20080293679A1

  公开（公告）日：2008-11-27

  Administering carotenoids, and in particular xanthophyll carotenoids, or analogs or derivatives of astaxanthin, lutein, zeaxanthin, lycoxanthin, lycophyll, or lycopene to a subject undergoing treatment with COX-2 inhibitor drugs may reduce at least a portion of the adverse side effects associated with administration of COX-2 selective inhibitor drugs. The carotenoids, or analogs or derivatives thereof may be administered to a subject prior to, at the same time as, or after the commencement of COX-2 selective inhibitor drug therapy. The carotenoids, or analogs or derivatives thereof may be administered to a subject concurrently with COX-2 selective inhibitor drugs therapy. The carotenoids, or analogs or derivatives thereof may be incorporated into pharmaceutical preparation in combination with the COX-2 selective inhibitor drug or may be administered separately. Administration of the analogs or derivatives described herein may reduce peroxidation of LDL and other lipids in the serum and plasma cell membranes of subjects undergoing COX-2 selective inhibitor drug therapy. Administration of the analogs or derivatives described herein may reduce the incidence of deleterious clinical cardiovascular events undergoing COX-2 selective inhibitor drug therapy.

  向正在接受COX-2抑制剂治疗的受试者施用类胡萝卜素，特别是黄质类胡萝卜素，或者是天然类胡萝卜素的类似物或衍生物，如虾青素、叶黄素、玉米黄质、莱科黄素、莱科菲或番茄红素，可能会减少与使用COX-2选择性抑制剂药物相关的不良副作用的至少一部分。这些类胡萝卜素，或者是其类似物或衍生物，可以在受试者开始接受COX-2选择性抑制剂药物治疗之前、同时或之后进行施用。这些类胡萝卜素，或者是其类似物或衍生物，可以与COX-2选择性抑制剂药物治疗同时进行施用。这些类胡萝卜素，或者是其类似物或衍生物，可以与COX-2选择性抑制剂药物组合在一起制成药物制剂，也可以单独施用。施用本文所述的类似物或衍生物可能会减少正在接受COX-2选择性抑制剂药物治疗的受试者血清和血浆细胞膜中低密度脂蛋白和其他脂质的过氧化。施用本文所述的类似物或衍生物可能会减少正在接受COX-2选择性抑制剂药物治疗的受试者发生有害的临床心血管事件的几率。
• Water-dispersible carotenoids, including analogs and derivatives
  申请人：Lockwood F. Samuel

  公开号：US20070015735A1

  公开（公告）日：2007-01-18

  A method used for synthesizing intermediates for use in the synthesis of carotenoid synthetic intermediates, carotenoid analogs, and/or carotenoid derivatives. The analog, derivative, or intermediate may be administered such that a subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In some embodiments, the invention may include methods for synthesizing chemical compounds including an analog or derivative of a carotenoid. The carotenoid analog or derivative may be synthetic. In some embodiments, a carotenoid analog or derivative may include at least one substituent. The substituent may enhance the solubility of the carotenoid analog or derivative such that the carotenoid analog or derivative at least partially dissolves in water.

  一种用于合成中间体的方法，用于合成类胡萝卜素合成中间体，类胡萝卜素类似物和/或类胡萝卜素衍生物。该类似物、衍生物或中间体可以被用于降低受试者因反应性氧化物种、反应性氮物种、自由基和/或非自由基相关疾病的风险。该类似物或类似物组合可以被用于抑制和/或改善任何涉及产生反应性氧化物种、反应性氮物种、自由基和/或非自由基的疾病。在某些实施例中，该发明可以包括用于合成化学化合物的方法，其中包括类胡萝卜素的类似物或衍生物。类胡萝卜素类似物或衍生物可以是合成的。在某些实施例中，类胡萝卜素类似物或衍生物可以包括至少一个取代基。该取代基可以增强类胡萝卜素类似物或衍生物的溶解度，使其至少部分溶解于水中。
• Carotenoid analogs and derivatives for the prevention of platelet aggregation
  申请人：Lockwood Samuel F.

  公开号：US20090124574A1

  公开（公告）日：2009-05-14

  The presently described embodiments are directed to compositions that include one or more carotenoid analogs or derivatives for use in the treatment of a disorder associated with platelet aggregation. Certain embodiments provide for the use of said carotenoid analogs or derivatives in preparing compositions suitable for use in such treatments. Further embodiments provide for pharmaceutical compositions that include one or more carotenoid analogs or derivatives in combination with one or more additional compositions or medicaments suitable for the treatment of a disorder associated with platelet aggregation. Yet farther embodiments provide for methods of treating a disorder associated with platelet aggregation that include administering to a subject who would benefit from such treatment pharmaceutical compositions suitable for inhibiting platelet aggregation in a subject undergoing said treatments, and that include carotenoid analogs or derivatives, optionally in combination with one or more additional antiplatelet agents.
• US7320997B2
  申请人：——

  公开号：US7320997B2

  公开（公告）日：2008-01-22
• US7345091B2
  申请人：——

  公开号：US7345091B2

  公开（公告）日：2008-03-18